CD56 Expression Is an Important Prognostic Factor in Multiple Myeloma Even with Bortezomib Induction
© 2018 S. Karger AG, Basel..
OBJECTIVES: In this retrospective study, we evaluated the impact of CD56, CD117, and CD28 expression on clinical characteristics and survival in newly diagnosed myeloma patients treated with bortezomib-based induction therapy.
METHODS: We analyzed 110 myeloma patients. Immunophenotype was determined using panels consisting of CD19/CD38/CD45/CD56/CD138 and CD20, CD28, and CD117 were used additionally. All samples were tested for recurrent chromosomal aberrations.
RESULTS: CD56, CD117, and CD28 expression rates were 71, 6, and 68%, respectively. The lack of CD56 expression was associated with light chain myeloma. The lack of CD117 expression was associated with elevated creatinine levels (p = 0.037). We discovered the correlation between CD 28 expression and female gender. The median progression-free survival (PFS) for patients with revised International Staging System stage 2 disease with CD56 expression or the lack of CD56 expression was 20.5 vs. 13.8 months (p = 0.03). In patients undergoing autologous hematopoietic stem cell transplantation (aHSCT), we found no difference in PFS and overall survival regarding the CD56 expression. We found no impact of CD117 and CD28 expression on PFS in patients regarding aHSCT.
CONCLUSIONS: Induction treatment incorporating bortezomib diminishes the negative impact of the lack of CD117 expression and aberrancy of CD28 but does not overcome the negative impact of the lack of CD56 expression.
| Errataetall: |
CommentIn: Acta Haematol. 2018;140(1):40-41. - PMID 30110676 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:139 |
|---|---|
| Enthalten in: |
Acta haematologica - 139(2018), 4 vom: 19., Seite 228-234 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Skerget, Matevz [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 25.03.2019 Date Revised 25.03.2019 published: Print-Electronic CommentIn: Acta Haematol. 2018;140(1):40-41. - PMID 30110676 Citation Status MEDLINE |
|---|
| doi: |
10.1159/000489483 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM285644122 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM285644122 | ||
| 003 | DE-627 | ||
| 005 | 20231225045901.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1159/000489483 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0952.xml |
| 035 | |a (DE-627)NLM285644122 | ||
| 035 | |a (NLM)29920491 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Skerget, Matevz |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a CD56 Expression Is an Important Prognostic Factor in Multiple Myeloma Even with Bortezomib Induction |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.03.2019 | ||
| 500 | |a Date Revised 25.03.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Acta Haematol. 2018;140(1):40-41. - PMID 30110676 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2018 S. Karger AG, Basel. | ||
| 520 | |a OBJECTIVES: In this retrospective study, we evaluated the impact of CD56, CD117, and CD28 expression on clinical characteristics and survival in newly diagnosed myeloma patients treated with bortezomib-based induction therapy | ||
| 520 | |a METHODS: We analyzed 110 myeloma patients. Immunophenotype was determined using panels consisting of CD19/CD38/CD45/CD56/CD138 and CD20, CD28, and CD117 were used additionally. All samples were tested for recurrent chromosomal aberrations | ||
| 520 | |a RESULTS: CD56, CD117, and CD28 expression rates were 71, 6, and 68%, respectively. The lack of CD56 expression was associated with light chain myeloma. The lack of CD117 expression was associated with elevated creatinine levels (p = 0.037). We discovered the correlation between CD 28 expression and female gender. The median progression-free survival (PFS) for patients with revised International Staging System stage 2 disease with CD56 expression or the lack of CD56 expression was 20.5 vs. 13.8 months (p = 0.03). In patients undergoing autologous hematopoietic stem cell transplantation (aHSCT), we found no difference in PFS and overall survival regarding the CD56 expression. We found no impact of CD117 and CD28 expression on PFS in patients regarding aHSCT | ||
| 520 | |a CONCLUSIONS: Induction treatment incorporating bortezomib diminishes the negative impact of the lack of CD117 expression and aberrancy of CD28 but does not overcome the negative impact of the lack of CD56 expression | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Autologous stem cell transplantation | |
| 650 | 4 | |a CD117 | |
| 650 | 4 | |a CD28 | |
| 650 | 4 | |a CD56 | |
| 650 | 4 | |a Immunophenotype | |
| 650 | 4 | |a Multiple myeloma | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 650 | 7 | |a CD56 Antigen |2 NLM | |
| 650 | 7 | |a NCAM1 protein, human |2 NLM | |
| 650 | 7 | |a Proteasome Inhibitors |2 NLM | |
| 650 | 7 | |a Bortezomib |2 NLM | |
| 650 | 7 | |a 69G8BD63PP |2 NLM | |
| 700 | 1 | |a Skopec, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a Zadnik, Vesna |e verfasserin |4 aut | |
| 700 | 1 | |a Zontar, Darja |e verfasserin |4 aut | |
| 700 | 1 | |a Podgornik, Helena |e verfasserin |4 aut | |
| 700 | 1 | |a Rebersek, Katarina |e verfasserin |4 aut | |
| 700 | 1 | |a Furlan, Tadej |e verfasserin |4 aut | |
| 700 | 1 | |a Cernelc, Peter |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Acta haematologica |d 1948 |g 139(2018), 4 vom: 19., Seite 228-234 |w (DE-627)NLM000152889 |x 1421-9662 |7 nnns |
| 773 | 1 | 8 | |g volume:139 |g year:2018 |g number:4 |g day:19 |g pages:228-234 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1159/000489483 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 139 |j 2018 |e 4 |b 19 |h 228-234 | ||